NCT00151073View on ClinicalTrials.gov

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2007

Conditions
Hormone-Refractory Prostate Cancer
Interventions
DRUG

Zoledronic acid

DRUG

Estramustine

DRUG

Docetaxel

Trial Locations (1)

48109

The University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER